Lead Product(s) : Resiquimod
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : STM-416 (Resiquimod), is a TLR7 and TLR8 agonist which is being invstigated for prevention of recurrence or progression after transurethral resection of bladder tumor (TURBT) in patients with non-muscle invasive bladder cancer (NMIBC)
Brand Name : STM-416
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 04, 2023
Lead Product(s) : Resiquimod
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Resiquimod,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : TransCon TLR7/8 Agonist is an investigational long-acting prodrug of resiquimod, a small molecule agonist of Toll-like receptors (TLR) 7 and 8 designed to provide sustained activation of intratumoral antigen-presenting cells driving tumor antigen present...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 11, 2022
Lead Product(s) : Resiquimod,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Resiquimod
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Ascendis Pharma A/S to Host Virtual R&D Program Update on December 14
Details : Resiquimod, a small molecule agonist of Toll-like receptors, is designed to provide sustained activation of intratumoral antigen presenting cells driving tumor antigen presentation and induction of immune stimulatory cytokines in the tumor.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 07, 2021
Lead Product(s) : Resiquimod
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?